Palo Alto Investors’s Neurocrine Biosciences NBIX Stock Holding History

Palo Alto Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.05M	Hold	18,117	–	–	0.42%	31
2026 Q1	$2.39M	Hold	18,117	–	–	0.37%	34
2025 Q4	$2.57M	Hold	18,117	–	–	0.36%	34
2025 Q3	$2.54M	Buy	18,117 +4,783	+36%	+$648K	0.47%	32
2025 Q2	$1.68M	Hold	13,334	–	–	0.36%	32
2025 Q1	$1.47M	Buy	+13,334	New	+$1.69M	0.28%	30

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Palo Alto Investors's NBIX Position: Q2 2026 in Review

Palo Alto Investors held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 18,117 shares worth $3.05M. The position accounts for 0.42% of the portfolio, ranked #31.

Palo Alto Investors first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Palo Alto Investors held 18,117 shares of Neurocrine Biosciences worth $3.05M as of Q2 2026.
Palo Alto Investors left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.42% of Palo Alto Investors's portfolio in Q2 2026, its #31 holding.
Palo Alto Investors first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.